Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous …
M Gardembas, P Rousselot, M Tulliez, M Vigier… - Blood, 2003 - ashpublications.org
In chronic myelogenous leukemia (CML) imatinib mesylate has been shown to selectively
inhibit the tyrosine kinase domain of the oncogenic bcr-abl fusion protein. Using this agent …
inhibit the tyrosine kinase domain of the oncogenic bcr-abl fusion protein. Using this agent …
Treatment of chronic myeloid leukemia in the imatinib era: perspective from a developing country
BACKGROUND There is paucity of data from developing countries on the efficacy and safety
of imatinib mesylate in chronic myeloid leukemia (CML). The primary objective of this study …
of imatinib mesylate in chronic myeloid leukemia (CML). The primary objective of this study …
Long‐term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study
K Ohnishi, C Nakaseko, J Takeuchi, S Fujisawa… - Cancer …, 2012 - Wiley Online Library
A prospective multicenter Phase II study was performed to examine the efficacy and safety of
imatinib therapy in newly diagnosed Japanese patients with chronic‐phase CML. Patients …
imatinib therapy in newly diagnosed Japanese patients with chronic‐phase CML. Patients …